Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa
- 1 July 1986
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 30 (1) , 122-126
- https://doi.org/10.1128/aac.30.1.122
Abstract
Serum bactericidal activity against 20 strains of Pseudomonas aeruginosa was studied in 10 volunteers after administration of imipenem (25 mg/kg), imipenem (25 mg/kg) plus amikacin (7.5 mg/kg), and ceftazidime (25 mg/kg) plus amikacin (7.5 mg/kg). Eight strains were susceptible and 12 were resistant to ticarcillin. Serum levels were measured microbiologically after 30 and 60 min and were, respectively, 97 and 46 micrograms/ml for imipenem given alone and 79 and 45 micrograms/ml for imipenem given with amikacin. Despite the very large dose of imipenem used, imipenem and imipenem plus amikacin appeared slightly less active than ceftazidime plus amikacin (P less than or equal to 0.1; Wilcoxon matched-pairs test), with respective median titers at 30 min of 1:128, 1:128, and 1:256 against ticarcillin-susceptible strains and 1:32, 1:32, and 1:64 against ticarcillin-resistant strains; however, more than 90% of the serum determinations, regardless of the regimen, had a serum bactericidal activity greater than or equal to 1:8. Amikacin significantly increased the rate of killing in serum of P. aeruginosa by imipenem. Imipenem plus amikacin appeared as effective as ceftazidime plus amikacin in reducing the viable counts of P. aeruginosa after 24 h of incubation.Keywords
This publication has 24 references indexed in Scilit:
- Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteersAntimicrobial Agents and Chemotherapy, 1986
- Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacinAntimicrobial Agents and Chemotherapy, 1986
- Efficacy and Safety of Imipenem/Cilastatin: A Review of Worldwide Clinical ExperienceClinical Infectious Diseases, 1985
- Use of discriminative models ofPseudomonas aeruginosa bacteremia in granulocytopenic rats for testing antimicrobial efficacyEuropean Journal of Clinical Microbiology & Infectious Diseases, 1985
- Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacinAntimicrobial Agents and Chemotherapy, 1984
- Role of antimicrobial synergism in infected granulocytopenic patientsEuropean Journal of Cancer and Clinical Oncology, 1984
- Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1984
- Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapyEuropean Journal of Cancer and Clinical Oncology, 1984
- Value of serum tests in combined drug therapy of endocarditisAntimicrobial Agents and Chemotherapy, 1983
- Serum Dilution Test for Bactericidal Activity. II. Standardization and Correlation with Antimicrobial Assays and Susceptibility TestsThe Journal of Infectious Diseases, 1977